Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ...

The agreement is for Kashiv BioSciences’ biosimilar candidate to Genentech and Novartis AG’s Xolair (omalizumab) in the ...